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Autosomal dominant polycystic liver disease (PCLD) is characterized bymultiple liver cysts and is caused
bymutations in PRKCSH (hepatocystin). Mechanisms of cystogenesis are unknown, but previous studies
have shown that hepatocystin is secreted in vitro. The goal of this study was to determine the fate of
hepatocystin in vivo. Using immunoprecipitation, we determined that mutant hepatocystin is secreted
from both apical and basolateral cell surface of MDCK cells stably transfected with mutant hepatocystin.
Analysis of 60 cyst fluid samples from polycystic livers using Western blot, MALDI-TOF MS or nLC-MS/
MS did not detect hepatocystin in liver cyst fluid. We did identify 163 ubiquitous serum proteins. No
paracrine or autocrine factors were recognized. Although cyst fluids vary greatly in protein concentration,
a PCLD specific protein pattern was not established. In conclusion, hepatocystin is not secreted in PCLD
liver cyst fluid, suggesting that mutant hepatocystin is either not produced or degraded intracellularly.
PCLD cysts develop from intralobular bile ductules and cyst fluid mainly contains common serum
proteins comparable to that of other polycystic diseases.
Keywords: PCLD • liver cyst fluid • PRKCSH • hepatocystin • protein profile • MALDI-TOF MS •
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Introduction
Polycystic liver disease (PCLD) is an autosomal dominant
inherited condition characterized by numerous fluid filled cysts
in the liver, without renal involvement.1 The main differential
diagnosis is autosomal dominant polycystic kidney disease
(ADPKD). Here, the predominant feature is the presence of
polycystic kidneys, though up to 80% of the patients develop
hepatic cysts as the primary extrarenal manifestation.2
PCLD is associated with mutations in PRKCSH.3,4 This gene
encodes hepatocystin, a protein that is involved in the folding
of glycoproteins in the endoplasmic reticulum. It serves as the
noncatalytic -subunit of R-glucosidase, an enzyme that cleaves
the two innermost glucoses from the mannose tree of glyco-
proteins.5 This releases the glycoprotein from calreticulin/
calnexin and makes it available for translocation to the Golgi.
This mechanism represents the quality control for correct
folding of glycoproteins in the ER (reviewed in ref 6).
Most hepatocystin mutations associated with PCLD lead to
premature termination of translation producing a truncated
protein. Transfection studies in HeLa cells have shown that
mutant, but not wild-type PRKCSH, results in a protein that
does not assemble with the R-subunit, loses retainment in the
ER and is secreted into the medium.7 It is unclear whether these
in vitro findings reflect the situation in PCLD, and whether
hepatocystin is secreted in vivo.
Recent developments in mass spectrometry technologies
have enabled analysis of differential proteomics, such as the
comparison between normal and disease status. This allows
identification of protein markers that may serve to identify a
specific physiological or pathological state. We used single-
dimension SDS-PAGE for protein separation in combination
with high-throughput techniques for protein identification in
liver cyst fluids. We performed proteomic analysis on a platform
of matrix-assisted laser desorption/ionization-time-of-flight
mass spectrometry (MALDI-TOF MS) and nanoscale liquid
chromatography tandem mass spectrometry (nLC-MS/MS).
This study was designed with the main aim to determine
whether hepatocystin is secreted in cyst fluid in vivo. We
hypothesized that similar to in vitro experiments, (mutant)
hepatocystin is secreted into hepatic cysts of patients carrying
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a mutant PRKCSH allele. Second, we set out to identify
substantially abundant proteins in cyst fluid from PCLD
patients in order to obtain a unique protein signature. In
addition, we hoped to identify autocrine and paracrine factors
that stimulate cyst formation and growth. The results may help
to clarify the mechanisms that drive the hepatic cystogenesis
and may aid in the identification of biomarkers of the disease.
Experimental Procedures
Development of Cell Lines. Madin-Darby canine kidney
(MDCK) cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum,
penicillin 100 U/mL and streptomycin 100 U/mL. We trans-
fected the cells with eukaryote expression vectors containing
wild-type and mutated PRKCSH7 using Fugene reagent (Roche,
Indianapolis, IN). Transfected clones expressing the introduced
genes were selected using G418 resistance. Stably transfected
MDCK cells were grown on an Anopore filter with a pore size
of 0.02 µm (Nalge Nunc International, Rochester, NY). Medium
was collected on the apical and basolateral side of the
membrane after 3, 6, 9, and 12 h and subsequently used for
immunoprecipitation experiments.
Immuoprecipitation. Aliquots with equal protein concentra-
tion were precipitated with 30 µL of anti-HA monoclonal
antibody (clone HA.11, Covance, Richmond, CA) bound to
protein G/agarose beads (Santa Cruz Biotechnology, Santa
Cruz, CA) for 16 h at 4 °C. Next, samples were centrifuged (3
min, 2000g, 4 °C), washed twice with 1 mL of lysis buffer
containing 0.1% Triton X-100, and subsequently washed once
with 0.5 mL of PBS. Samples were then analyzed on Western
blot using anti-HA antibody.
Western Blot. Proteins resolved by SDS-PAGE were trans-
ferred onto a Protran nitrocellulose membrane (Whatman Inc.,
Florham Park, NJ). Membranes were blocked with 5% low-fat
milk and incubated overnight with primary antibodies, directed
against Hemagglutinin (HA)-tag (clone HA.11, Covance, Rich-
mond, CA) or hepatocystin (BD Transduction Laboratories, San
Jose, CA), followed by incubation with appropriate secondary
antibodies labeled with horseradish peroxidase (HRP). Second-
ary antibodies were visualized using ECL Western blotting
detection reagents (GE Healthcare Limited, Buckinghamshire,
U.K.) and Hyperfilm MP (Amersham Biosciences UK Ltd.,
Buckinghamshire, U.K.).
Patients and Samples. PCLD was diagnosed when (1) more
than 20 liver cysts were seen on abdominal computer tomog-
raphy and the formal ultrasonographic criteria for ADPKD were
not applicable8 or (2) mutations were found in PRKCSH. We
collected 60 cyst fluid samples from 25 patients who underwent
percutaneous cyst aspiration or laparoscopic cyst fenestration.
The patient group consisted of 16 PCLD patients (50 samples,
all female), 3 ADPKD patients (3 samples, 2 female/1 male) and
6 patients with isolated liver cysts who did not meet the PCLD
or ADPKD criteria (7 samples, 4 female/2 male). Samples were
frozen in aliquots to prevent recurrent thawing and stored at
-20 °C.
Genotyping. Patients included in this study were screened
for PCLD mutations by extracting genomic DNA from periph-
eral blood leukocytes (Gentra Systems, Minneapolis, MN) and
genotyping for PRKCSH as described earlier.9 From the 16
PCLD patients, 7 patients showed a mutation in PRKCSH. The
patients with isolated liver cysts were all wild-type for PRKCSH.
Routine Chemistry. Total protein concentration and albu-
min concentration was determined in all fluids using an Aeroset
2.0 automated analyzer (Abbott Laboratories, Abbott Park, IL).
Protein Profiling. All cyst fluid samples were subjected to
SDS-PAGE analysis. The samples were albumin-depleted and
subsequently concentrated to prevent disruption of experi-
ments by high albumin concentrations. Albumin was removed
from cyst fluids using ProteoExtract Albumin removal kit
(Calbiochem, Darmstadt, Germany) and the samples were
concentrated using YM3 Microcon centrifugal filter devices
(Millipore, Billerica, MA) according to manufacturer’s instruc-
tions. After separation on a 12% polyacrylamide gel electro-
phoresis, samples were either processed for Western blot
analysis or proteins were in-gel-digested with trypsin followed
by matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) for identification of
proteins.
In-Gel Trypsin Digestion. SDS-PAGE gels were fixed in 12%
TCA, stained with Coomassie Brilliant Blue G250 and destained
in 20%methanol/7%acetic acid. Gels were then carefully sealed
in 23% ammonium sulfate and stored at 4 °C until further use.
Each of the protein bands visible on SDS-PAGE gels was
analyzed in 10 different samples. Spots of interest were cut from
the gels (approximately 1.5 mm3) using a scalpel or a pipet.
Gel pieces were washed with 25 mM ammonium bicarbonate
and dehydrated with increasing concentrations of acetonitrile.
Next, gel pieces were rehydrated on ice with∼15 ng/µL Trypsin
Gold (Promega, Madison, WI) in 25 mM ammoniumbicarbon-
ate/5 mM n-octyl--D-glucopyranoside. Excess trypsin solution
was removed, and pieces were covered with 25 mM ammoni-
umbicarbonate/5 mM n-octyl--D-glucopyranoside and incu-
bated overnight at 37 °C. Peptides were extracted using 50%
acetonitrile/0.5%trifluoroacetic acid (TFA)/5 mM n-octyl--D-
glucopyranoside. After 1 h incubation and 2 min sonification,
the liquid was transferred to a new tube, and extracts were
dried using a vacuum centrifuge.
MALDI-TOF MS. Samples were dissolved in 0.1% TFA,
spotted on an MTP ground steel plate, covered with a matrix
solution containing 20 mg/mL 4-hydroxy-R-cyanocinnamic
acid in 50% acetonitrile/0.05% TFA, and allowed to air-dry.
Series of eight samples were spotted around one external
calibration mixture. This calibration mix contained 1.26 mM
bradikinin, 1.26 mM P14R, 0.19 mM angiotensin and 0.95 mM
ACTH in matrix solution. After protein spotting, the sample
plate was transferred into the mass spectrometer (Bruker Biflex
III MALDI-TOF MS, Bruker Daltonics Inc., Billerica, MA) and
spectra were obtained in the reflectron mode. All relevant peaks
seen on the MALDI-TOF MS spectrum were manually an-
notated as their monoisotopic peptide peaks and the respective
m/z values were stored in a peak search list using the X-TOF
program (Version 5.1.0, Bruker Daltonics, Billerica, MA). The
search list representing the protein peptide mass fingerprint
was compared to the Swiss-Prot database (version 20040730)
using BioTools (Version 2.01, Bruker Daltonics, Billerica, MA)
and the MASCOT search algorithm (Version 1.6, Matrix Science,
Inc., Boston, MA). Search parameters were set to look for
proteins from Homo sapiens only, with methionine oxidation
as a possible modification and allowing 1 trypsin miscleavage.
Protein identifications were assigned a Mowse score calculated
by -10 Log(P), were P is the probability that the observed
match is a random event.10 A Mowse score greater than 53 with
a protein mass tolerance e0.2 Da was considered significant
(p< 0.05). Resulting hits were scrutinized based on their Mowse
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score, sequence coverage, and the similarity between theoreti-
cal and experimental molecular weight obtained from gel
electrophoresis. Keratin identifications were excluded since
they are likely to be contaminants in MALDI-TOF MS experi-
ments.11
nLC-MS/MS. A pool of 5 cyst fluid samples from different
patients was analyzed using nanoflow liquid chromatography
linear ion trap Fourier transform-ion cyclotron resonance mass
spectrometry (nLC-LIT FT-ICR MS). The proteins were sepa-
rated on a 12% SDS-PAGE gel. The gel was divided into 5 pieces
(front-23 kDa, 23-30 kDa, 30-50 kDa, 50-70 kDa, 70 kDa-high
end), which were subsequently in-gel-reduced with 10 mM
dithiotreitol, alkylated with 50 mM iodoacetamide and digested
with trypsin. Prior to nLC-MS/MS analysis, samples were
purified and desalted using Stage tips.12 Peptides were analyzed
using the nLC LTQ FTMS (Thermo Scientific, Waltham, MA)
equipment of the Nijmegen Proteomics Facility (NPF, www.
proteomicsnijmegen.nl) and RAW spectrum files were con-
verted with the aid of DTAsupercharge (http://msquant.
sourceforge.net/) into a Mascot generic peak list. Peptides and
proteins were identified using the Mascot search program
(Version 2.1.03, Matrix Science Inc., Boston, MA, USA) and the
NCBInr database (version 20070212, www.ncbi.nlm.nih.gov)
using H. sapiens taxonomy. The search algorithm was set to
perform a tryptic search allowing 2 miscleavages and searched
for carbamidomethyl modifications on cysteine residues and
possible oxidation of methionine and deamidation of glutamine
and asparagine, with a mass accuracy of 20 ppm for the ICR
cell and 0.8 Da for the LIT of the instrument. False-discovery
rates (FDR) were estimated by Mascot searches performed
against the reversed protein database using the criteria men-
tioned above. To validate the protein hits resulting from
Mascot, the files were reanalyzed using PROVALT.13 This
automated program takes large MS data sets and reorganizes
them by grouping together peptides according to their pre-
dicted matching protein. FDR calculations by PROVALT provide
a reasonable balance between the number of correct and
incorrect protein assignments. In this study, the FDR was set
at 1%. PROVALT clusters proteins together in homologous
groups. From each group, only the protein identified with the
most peptides per protein was taken into account for further
analyses.
The annotation of protein cellular localization and biological
function was performed using gene ontology (GO) biological
process and the GO cellular component terms.14 GO analysis
was performed using ProteinCenter (Proxeon Biosystems A/S,
Odense Denmark, www.proxeon.com).
Results
Mutated Hepatocystin Is Secreted by MDCK Cells. To
determine whether hepatocystin can be secreted in cyst fluid,
we first analyzed on which side of the polarized epithelial cell
hepatocystin is secreted. To this end, we stably transfected
MDCK cells with epitope-tagged wild-type and mutant PRK-
CSH. Immunoprecipitation and Western blot analysis con-
firmed expression of full-length (wild-type) and truncated
(mutant) hepatocystin by these cell lines (Figure 1A). Next, we
cultured the cells on a membrane and analyzed medium on
the apical and basolateral side of the cells. We found that
truncated hepatocystin is secreted into both the apical and
basolateral medium. Secretion was both substantial and rapid,
detectable only 3 h after changing the medium. In contrast,
full-length hepatocystin was retained in the cells. The presence
of the HA-tag after 12 h probably represents loss through cell
lysis.
General Chemistry of Human Cyst Fluids. A total of 60 liver
cyst fluids were included in this study (16 PCLD patients, 50
samples; 3 ADPKD patients, 3 samples; 6 patients with isolated
liver cysts, 7 samples). We detected 7 heterozygous PRKCSH
mutation carriers among 16 tested PCLD patients, while the
remaining patients were wild-type for PRKCSH. Total protein
and albumin concentrations were determined in all fluid
samples. Both parameters were within the range of normal
values in serum, but showed great variability. The mean total
protein content of hepatic cysts was 25.2 g/L (range 0.2-84.4
g/L), while mean albumin value was 12.9 g/L (range 0-44 g/L).
There were large differences between patients, but also between
individual cysts obtained from the same patient. We observed
no differences between PCLD, ADPKD and isolated liver cyst
content.
Hepatocystin Is Absent in PCLD Liver Cyst Fluid. To study
the presence of hepatocystin in liver cyst fluid, we subjected
17 PCLD cyst fluid samples (6 PRKCSH wild-type, 11 PRKCSH
mutants) to Western blot analysis followed by immunostaining
for hepatocystin. We failed to detect mutant hepatocystin in
Figure 1. Immunoblot analysis of hepatocystin secretion by
MDCK cells. (A) HA-tagged wild-type (full-length) and mutant
(truncated) hepatocystin are expressed in stably transfected
MDCK cells. Introduced hepatocystin was detected on immuno-
blot using anti-HA tag antibody. (B) Mutated hepatocystin is
secreted form the apical and the basolateral side of MDCK cells.
Stably transfected MDCK cells were grown on an Anopore
membrane. After 3, 6, 9, or 12 h, medium was collected from
the apical and the basolateral side and immunoprecipitated using
an antibody against HA-tag. Protein was visualized on immuno-
blot with an anti-HA-tag antibody. Notice that full-length (wild-
type) hepatocystin is not secreted by the MDCK cells.
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fluids from PRKCSH mutation carriers. Likewise, none of the
cyst fluids demonstrated wild-type hepatocystin staining,
indicating the absence of hepatocystin in these samples (Fig-
ure 2).
MALDI-TOF MS Analysis. Next, we determined the protein
profile of 60 cyst fluids (50 PCLD, 3 ADPKD and 7 isolated liver
cysts) by one-dimensional SDS-PAGE gel electrophoresis and
protein staining with Coomassie Brilliant Blue (Figure 3). We
compared the protein profiles with profiles from three healthy
control sera. The cyst fluid profiles revealed highly similar
images consistent with a serum-like pattern. We observed no
staining pattern unique to fluids derived from either group.
Electrophoresis of cyst fluids revealed 25 unique protein
bands. To limit variation, we handpicked each band 10 times
from the gels. Samples were subsequently analyzed using in-
gel trypsin digestion and MALDI-TOF MS. We identified a total
of 10 proteins (Table 1). We detected transferrin and ferritin,
both involved in iron transport, and apolipoprotein A-1 and
transthyretin, which participate in cholesterol and thyroxine
transport, respectively. Furthermore, we identified albumin,
R-1-antitrypsin, and complement C3 in addition to fibronectin
and fibrinogen. One sample contained hemoglobin indicating
that the cyst had bled. All proteins identified are commonly
present in serum. All identifications were confirmed with
nLC-MS/MS analysis (see below), although R-1-antitrypsin was
not a first hit in its protein group. Hepatocystin was not
detected in our samples.
Nano-LC MS/MS. Finally, we analyzed a pool of 5 PCLD
liver cyst fluids with one-dimensional SDS-PAGE gel electro-
phoresis followed by nLC–MS/MS. In addition to the 10
proteins already detected by MALDI-TOF MS, nLC-MS/MS
demonstrated the presence of 153 unique proteins, when likely
contaminants such as keratins were omitted (Supplementary
Table 1, the first hit in each group is highlighted in red, likely
contaminants are listed in gray). Again, hepatocystin was not
present.
Classification of the identified proteins according to their
Gene Ontology (GO) terms showed that of the 163 identified
proteins 119 proteins are involved in metabolism (73%), 67
proteins are involved in regulation of biological processes
(41%), and 63 proteins are involved in defense response (39%)
(Figure 4A). Next, we classified proteins according to their
cellular component GO annotation. This revealed that most
identified proteins were extracellular (127 proteins, 78%), or
associated with membranes (52 proteins, 32%). Also, 36 pro-
teins were associated with protein complexes (22%) (Figure 4B).
Discussion
Here we show that (1) mutant hepatocystin is secreted from
MDCK cells on the apical as well as on the basolateral side; (2)
liver cyst fluids from PCLD, ADPKD and isolated liver cysts vary
greatly in total protein and albumin concentration, but show
similarity in protein profile when visualized on SDS-PAGE gel
electrophoresis; (3) none of the fluids analyzed contain hepa-
tocystin; and (4) the 163 proteins identified by MALDI/TOF MS
and nLC-MS/MS are mainly extracellular or membrane bound
and involved in metabolism and regulation of biological
processes.
Previous research has shown that mutant hepatocystin can
be secreted from HeLa cells.7 In this study, we confirm this
finding and we show in addition that mutant hepatocystin is
secreted on the apical as well as on the basolateral side of
MDCK cells. This suggests that cysts from patients harboring
a PRKCSH mutation theoretically might contain mutant
hepatocystin.
We used 3 different techniques to analyze hepatocystin
presence in human liver cyst fluid, but failed to identify
hepatocystin in our samples. This discrepancy can be explained
two-fold. First, the in vitro experiments comprise artificial
introduction and overexpression of protein, and might not have
been the correct reflection of the in vivo setting. Second, high-
abundance proteins such as albumin, which constitutes 50%
of protein content in cyst fluids, are a disturbing factor in either
of the used techniques. We depleted all samples from albumin,
but samples were not completely dealbuminized as shown by
both MALDI-TOF MS and nLC-MS/MS analysis. Therefore,
would hepatocystin be bound to albumin, it would have been
detected as well by these techniques. Finally, we performed a
Figure 2. Western blot analysis of hepatocystin in cyst fluids. A
representative image is shown of four PCLD cyst fluids (num-
bered lanes) and a positive control (+). Albumin-depleted and
concentrated samples were subjected to Western blot analysis
followed by immunostaining of hepatocystin. No hepatocystin
was detected in the cyst fluids. We used cholangiocyte whole
cell lysate for positive control. Molecular mass is indicated on
the left (kDa).
Figure 3. Protein profile of PCLD cyst fluid. A representative
image is shown of six PCLD cyst fluids (numbered lanes). Cyst
fluid samples were albumin-depleted and subsequently concen-
trated to prevent disruption by high albumin concentrations. After
SDS PAGE electrophoresis, proteins were visualized using Coo-
massie Brilliant Blue. Notice highly similar and serum-like protein
profiles for all patients. Molecular mass is indicated on the left
(kDa).
Hepatocystin Is Not Secreted in PCLD Cyst Fluid research articles
Journal of Proteome Research • Vol. 7, No. 6, 2008 2493
Western blot analysis with immunostaining for hepatocystin
on non-albumin-depleted samples (n ) 6, data not shown).
Once again, hepatocystin was not detected. Altogether, these
data suggest that hepatocystin is not secreted in liver cyst fluid.
This indicates that hepatocystin is either contained in the cells
lining the cysts or is not produced at all. Recently, we have
shown that hepatocystin is absent in cyst epithelia of patients
harboring a truncating mutation in hepatocystin.15 Thus, it
seems that despite the dominant inheritance pattern of the
disease, hepatocystin is not produced in cyst epithelia. Further
research is needed to clarify the mechanisms involved. One of
the possibilities is that mutated PRKCSHmRNA from cyst lining
is subjected to nonsense mediated RNA decay (reviewed in ref
16).
In 1982, Patterson et al. described the biochemical charac-
teristics of two liver cyst fluid samples from a single PCLD
patient.17 In line with our results, they found a serum like
protein pattern and identified R-1-antitrypsin, R-2-macroglo-
bulins, hepatoglobin, albumin, transferrin and poly IgG and
IgA in the fluids. Several studies have shown that ADPKD
kidney cyst fluid contain cytokines and growth factors both of
which contribute to cyst formation and cyst growth when
imposed on kidney cell lines or cells from ADPKD cyst
epithelium.18–22 We did not observe cytokines or growth factors
in our samples, but we did not use specific enzyme-linked
immunosorbent assays in order to detect these molecules. The
Gene Ontology classification of the proteins identified by
nLC-MS/MS showed that most proteins we identified are
involved in metabolism (73%), regulation of biological pro-
cesses (41%), and defense response (39%). Only 9% of proteins
identified play a role in either stimulation or inhibition of cell
proliferation. However, apart from proteins, other biological
factors present in the cyst fluids, such as cAMP or lipids, may
contribute to cystogenesis.23–25
Conclusion
The results presented here demonstrate that hepatocystin
is not secreted in liver cyst fluid from PRKCSH mutated PCLD
patients, despite the central role of hepatocystin in PCLD. This
suggests mutant hepatocystin is either not produced or de-
graded intracellularly. We have identified a large number of
ubiquitous serum proteins in liver cyst fluid, even though PCLD
cysts develop from the intralobular bile ducts. Many of the
identified proteins fulfill a role in metabolism and paracrine
or autocrine proliferation factors were not recognized. Fur-
thermore, PCLD cyst fluid resembles that of ADPKD and
isolated liver cyst fluid indicating a common pathway for
cystogenesis.
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Table 1. Overview of Proteins Identified by MALDI-TOF MS Analysisa
protein
Swiss-Prot
accession no.
average Mowse
score no. hits
no. peptides
matched
sequence
coverage (%)
nLC-MS/MS
confirmation
Fibronectin P02751 95 3/10 22/42 19 Yes
Serotransferrin P02787 109 2/10 18/29 28 Yes
Complement C3 P01024 142 2/3 21/35 22 Yes
Serum albumin P02768 121 8/10 16/21 34 Yes
R-1-antitrypsin P01009 117 10/10 15/40 56 Yes
Fibrinogen  chain P02675 90 6/10 21/34 41 Yes
Apolipoprotein A-I P02647 119 7/10 13/24 53 Yes
Ferritin light chain P02792 88 1/10 8/24 37 Yes
Transthyretin P02766 65 2/10 5/22 74 Yes
Hemoglobin  chain P68871 74 1/10 6/24 51 Yes
a No. hits represents the number of identifications of the particular protein in relation to the number of samples analyzed. No. peptides matched are
based on the annotation in the hit with the highest Mowse score. Total sequence coverage is calculated from the peptides matched in all hits for a specific
protein.
Figure 4. Classification of the proteins identified in PCLD cyst
fluid. A total of 163 proteins were identified from a pool of 5 PCLD
cyst fluids using one-dimensional SDS-PAGE gel electrophoresis
followed by nLC-MS/MS. Proteins were categorized according
to their Gene Ontology terms for (A) involvement in biological
processes and (B) predicted cellular localization.
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